Alx oncology and quantum leap healthcare collaborativetm announce first patient dosed in the i-spy-p1 trial in breast cancer

South san francisco, calif. , march 14, 2023 /prnewswire/ -- alx oncology holdings inc., ("alx oncology") (nasdaq: alxo), a clinical-stage immuno-oncology company developing therapies that block the cd47 checkpoint pathway, and quantum leap healthcare collaborative ("quantum leap") today announced that the first patient has been dosed in the i-spy-p1-trial for the treatment of patients with unresectable or metastatic her2-positive and her2-low breast cancer.
ALXO Ratings Summary
ALXO Quant Ranking